Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal

Medical,Research,And,Development,Center:,Female,Asian,Scientist,Using,Microscope

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Novo Nordisk A/S (NYSE:NVO) and Omeros on Wednesday announced an asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) for rare blood and kidney disorders.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.